XRCC1基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系  

Predictive value of XRCC1 polymorphisms in advanced non-small ccell lung cancer patients receiving platinum-based chemotherapy

作　　者：邱立新[1,2] 钱晓萍[1,2] 刘宝瑞[1,2] 胡文静[2] 杨阳[2] 禹立霞[2] 刘新姿[1,2] 严文跃[1,2] 

机构地区：[1]南京医科大学鼓楼临床医学院肿瘤中心,江苏南京210008 [2]南京大学医学院附属鼓楼医院肿瘤中心,江苏南京210008

出　　处：《现代肿瘤医学》2009年第2期263-265,共3页Journal of Modern Oncology

摘　　要：目的:研究DNA修复基因XRCC1的T-77C和Argl94Trp多态性与晚期肺癌患者铂类药物化疗敏感性的关系。方法:收集经病理学确诊的、接受铂类药物为基础的化疗的晚期肺癌患者107例,提取外周血DNA,用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)技术检测基因型,分析各基因型与疗效的关系。结果:XRCC1-77位点携带至少1个C等位基因患者的化疗有效率较野生型者提高约46%,但未达到统计学意义(OR=1.46,95%CI:0.56-3.79,P=0.441)。XRCC1 194位点携带至少1个Trp等位基因患者的治疗有效率是野生型者的2.51倍(OR=2.51,95%CI:1.12-5.62,P=0.025)。结论:XRCC1 Argl94Trp多态性与晚期肺癌铂类药物化疗敏感性相关,但未能发现XRCC1 T-77C多态性与化疗疗效存在明显关联。Objective：To investigate the association between XRCC1 T -77C and Argl94Trp polymorphisms and chemotherapy sensitivity in advanced lung cancer patients receiving platinum - based chemotherapy. Methods： Total of 107 advanced lung cancer patients receiving platinum - based chemotherapy were involved. DNA of peripheral blood leukoeytes was obtained, and genotypes were detected by PCR - RFLP method. The association between genotypes and response rate was evaluated. Results： Compared with the TT genotype, XRCC1 - 77 C - allele carriers had a roughly 46 % increased efficancy but with no statistical significance （OR = 1.46, 95% CI： 0.56-3.79, P =0.441 ） ; XRCC1 194 Trp carriers had a significant higher response rate than the wild genotype carriers （OR= 2.51, 95% CI： 1.12 -5.62,P = 0.025）. Conclusion： XRCC1 Argl94Trp polymorphism has a significant impact on response rate in advanced NSCLC patients treated with platinum- based chemotherapy. However, no association was found between the XRCC1 T- 77C polymorphism and response rate.

关 键 词：XRCC1 多态性 非小细胞肺癌 化疗敏感性 

分 类 号：R730.23[医药卫生—肿瘤] R734.2[医药卫生—临床医学]